BRIEF-Halozyme Reiterates 2024 Financial Guidance And Raises 2025 And Multi-Year Financial Guidance

Reuters01-08

Jan 8 (Reuters) - Halozyme Therapeutics Inc HALO.O:

HALOZYME REITERATES 2024 FINANCIAL GUIDANCE AND RAISES 2025 AND MULTI-YEAR FINANCIAL GUIDANCE
HALOZYME THERAPEUTICS INC: ANNOUNCES NEW $250 MILLION ACCELERATED SHARE REPURCHASE
HALOZYME THERAPEUTICS: RAISES 2025 FINANCIAL GUIDANCE RANGES FOR TOTAL REVENUE TO $1,150 - $1,225 MILLION
HALOZYME THERAPEUTICS INC: OUTLOOK 2025 ADJUSTED EPS $4.95 TO $5.35

Source text: ID:nPncbv3GDa

Further company coverage: HALO.O

((Reuters.Brief@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2501127725?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-08 20:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501127725","market":"us","top_or_hot":-1,"title":"BRIEF-Halozyme Reiterates 2024 Financial Guidance And Raises 2025 And Multi-Year Financial Guidance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Halozyme Reiterates 2024 Financial Guidance And Raises 2025 And Multi-Year Financial Guidance</title></head><body><p><span>Jan 8 (Reuters)</span><span> - </span>Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>HALO.O</span>:</p><ul><li><p>HALOZYME REITERATES 2024 FINANCIAL GUIDANCE AND RAISES 2025 AND MULTI-YEAR FINANCIAL GUIDANCE</p></li><li><p>HALOZYME THERAPEUTICS INC: ANNOUNCES NEW $250 MILLION ACCELERATED SHARE REPURCHASE</p></li><li><p>HALOZYME THERAPEUTICS: RAISES 2025 FINANCIAL GUIDANCE RANGES FOR TOTAL REVENUE TO $1,150 - $1,225 MILLION</p></li><li><p>HALOZYME THERAPEUTICS INC: OUTLOOK 2025 ADJUSTED EPS $4.95 TO $5.35</p></li></ul><p>Source text: <span>ID:nPncbv3GDa</span></p><p>Further company coverage: <span>HALO.O</span></p><p> ((Reuters.Brief@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Halozyme Reiterates 2024 Financial Guidance And Raises 2025 And Multi-Year Financial Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Halozyme Reiterates 2024 Financial Guidance And Raises 2025 And Multi-Year Financial Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-08 20:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA4X770Z:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Halozyme Reiterates 2024 Financial Guidance And Raises 2025 And Multi-Year Financial GuidanceJan 8 (Reuters) - Halozyme Therapeutics Inc HALO.O:HALOZYME REITERATES 2024 FINANCIAL GUIDANCE AND ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA4X770Z:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA4X770Z:1","article_id":"2501127725","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501127725","pubTimestamp":1736338652,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Halozyme Reiterates 2024 Financial Guidance And Raises 2025 And Multi-Year Financial GuidanceJan 8 (Reuters) - Halozyme Therapeutics Inc HALO.O:HALOZYME REITERATES 2024 FINANCIAL GUIDANCE AND RA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","HALO":"奥洛兹美医疗"},"translate_title":"简介-Halozyme重申2024年财务指引并提高2025年和多年财务指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":0.9},"content_text":"BRIEF-Halozyme Reiterates 2024 Financial Guidance And Raises 2025 And Multi-Year Financial GuidanceJan 8 (Reuters) - Halozyme Therapeutics Inc HALO.O:HALOZYME REITERATES 2024 FINANCIAL GUIDANCE AND RAISES 2025 AND MULTI-YEAR FINANCIAL GUIDANCEHALOZYME THERAPEUTICS INC: ANNOUNCES NEW $250 MILLION ACCELERATED SHARE REPURCHASEHALOZYME THERAPEUTICS: RAISES 2025 FINANCIAL GUIDANCE RANGES FOR TOTAL REVENUE TO $1,150 - $1,225 MILLIONHALOZYME THERAPEUTICS INC: OUTLOOK 2025 ADJUSTED EPS $4.95 TO $5.35Source text: ID:nPncbv3GDaFurther company coverage: HALO.O ((Reuters.Brief@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501127725"}